RecruitingNot Applicable

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

United States, Ghana, Tanzania130 participantsStarted 2025-03-13

Plain-language summary

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Who can participate

Age range6 Months – 6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants with confirmed Sickle Cell Disease.
✓. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
✓. Willing and able to provide informed consent
✓. Ability to comply with study related evaluations and follow-up visits.

What they're measuring

Measles Seroconversion Rates 8 Weeks After MV1 and MV2 Vaccinations

Timeframe: From enrollment to the end of sample collection at 8 weeks

Trial details

NCT IDNCT07356050

SponsorChildren's Hospital Medical Center, Cincinnati

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Teresa Latham

513-803-7922 Teresa.Latham@cchmc.org

View on ClinicalTrials.gov More Sickle Cell Disease trials